NOVOPEN Echo Plus Insulin Pen

Product Information

On interoperability with connective devices, Dr Griffin says: “Traditionally a person living with diabetes could see their glucose data in one place and would have needed to keep a manual log of their insulin data – often on paper or on a different platform.

User guide - Novo Nordisk User guide - Novo Nordisk

NovoPen ® 6 and NovoPen Echo ® Plus automatically record accurate and reliable insulin dosing information, giving people insight into their own data, and enabling more productive conversations with their healthcare provider, that can lead to better health outcomes.The kid-friendly Echo Plus allows for half-unit dosing and a maximum 30-unit injection, whereas the NovoPen 6 has a minimum dose of one unit and a maximum dose of 60 units. Over time, these new connected pens will replace the NovoPen 5 and current NovoPen Echo. Attachment for Disposable Pens Everyone with type 1 diabetes, and some people with type 2 diabetes or gestational diabetes, needs to take insulin to help manage their blood glucose levels. This reduces the chances of getting the symptoms of high blood glucose ( hyperglycaemia) and serious long-term problems that can damage the heart, kidneys, eyes, nerves and feet.

About long-acting insulin - NHS

In 2021 Novo Nordisk submitted an application to the Health Service Executive for reimbursement on the NovoPen ® 6 and NovoPen Echo ® Plus and we are still awaiting an outcome from that process. In the meantime, we believe it is important to make NovoPen ® 6 and NovoPen Echo ® Plus available now to those people who wish to use this technology to help manage their diabetes.Glooko: In January 2017,Novo Nordisk and Glooko announced a partnershipto develop digital diabetes tools together. Since that time, they have launched the Cornerstones4Care app, and the two will continue to work together as Novo Nordisk brings its connected insulin pens to market. Earlier this year, Glooko received FDA clearance for a basal insulin dosing advice app, and we hope to see that come to market at some point. Currently, insulin injection dosing information is manually recorded in a logbook or app. However, in clinical practice, incomplete or inaccurate information on insulin dosing and timing can be a significant barrier to optimising glycaemic control. Smart insulin pens are reusable devices that automatically record when a person has injected insulin, including how much has been injected and at what time of the day.

Novopen-echo-plus-IR 8-4261-41-050-2 - Novo Nordisk

Long-acting insulin starts to work after 30 minutes to 4 hours, depending on the type. It usually lasts for 16 to 24 hours, depending on the type and your dose. You'll usually take it once or twice a day. Insulin is a hormone made in your pancreas, which is a gland behind the stomach. It helps your body use glucose (sugar) for energy. The devices have a dose memory display which shows the amount of time that has passed since the last dose, and they can show a person when a dose has been missed. Results from an observational study indicate that using NovoPen 6 to administer their insulin could give people living with type 1 diabetes close to two extra hours of improved glucose levels (measured as HbA 1c 3.9 – 10.0 mmol/L) per day, with a reduction in time spent in hyperglycaemia (measured as HbA 1c >10 mmol/L) and level 2 hypoglycaemia (measured as HbA 1c <3.0 mmol/L). A further analysis looking at missed bolus doses (insulin that is specifically taken at mealtimes) indicated that NovoPen 6 decreased the average daily number of missed doses by 43% (p=0.002) by the end of the study.Visit www.diabeteswhatsnext.ie for more information on living with diabetes and NovoPen ® 6 and NovoPen Echo ® Plus smart insulin pens. Diabetes Novo Nordisk NovoPen NovoPen Ech Results from an observational study indicate that using NovoPen® 6 to administer their insulin could give people living with type 1 diabetes close to two extra hours of improved glucose levels (measured as HbA1c 3.9 – 10.0 mmol/L) per day, with a reduction in time spent in hyperglycaemia (measured as HbA1c >10 mmol/L) and level 2 hypoglycaemia (measured as HbA1c <3.0 mmol/L).